KINGWORLD MEDICINES GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.55 HKD | +1.85% |
|
+10.00% | -12.70% |
| 04-23 | Kingworld Medicines Posts 68% Jump in 2023 Profit | MT |
| 03-27 | Kingworld Medicines Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 | CI |
| Sales 2022 | 958M 132M 1.03B 10.55B | Sales 2023 | 1.08B 149M 1.17B 11.88B | Capitalization | 356M 49.23M 385M 3.93B |
|---|---|---|---|---|---|
| Net income 2022 | 22M 3.04M 23.76M 242M | Net income 2023 | 38M 5.25M 41.05M 419M | EV / Sales 2022 | 0.52 x |
| Net Debt 2022 | 34.51M 4.77M 37.27M 380M | Net Debt 2023 | 160M 22.15M 173M 1.77B | EV / Sales 2023 | 0.48 x |
| P/E ratio 2022 |
20
x | P/E ratio 2023 |
8.89
x | Employees | 1,002 |
| Yield 2022 |
2.9% | Yield 2023 |
5.34% | Free-Float | 33.63% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.85% | ||
| 1 week | +10.00% | ||
| Current month | +5.77% | ||
| 1 month | +5.77% | ||
| 3 months | -5.17% | ||
| 6 months | -28.57% | ||
| Current year | -12.70% |
1 week
0.50
0.56
1 month
0.490.56
Current year
0.490.67
1 year
0.490.92
3 years
0.371.10
5 years
0.371.19
10 years
0.372.90
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Zhi Fang
CIO | Chief Investment Officer | 42 | 31/07/15 |
Zhi Hui Huang
AUD | Comptroller/Controller/Auditor | 63 | - |
Hon Wan Chan
AUD | Comptroller/Controller/Auditor | 64 | 24/06/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheuk Lam Wong
BRD | Director/Board Member | 56 | 04/11/10 |
Lok San Chan
FOU | Founder | 61 | 31/12/95 |
Li Sheng Zhao
FOU | Founder | 66 | 31/12/95 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 0.55 | +1.85% | 1 212 000 |
| 29/04/24 | 0.54 | 0.00% | 1,036,000 |
| 26/04/24 | 0.54 | +1.89% | 956,000 |
| 25/04/24 | 0.53 | +6.00% | 1,240,000 |
| 24/04/24 | 0.5 | 0.00% | 8,000 |
Delayed Quote Hong Kong S.E., April 30, 2024 at 09:08 am
More quotes
Kingworld Medicines Group Limited is an investment holding company principally engaged in the distribution and sales of pharmaceutical and healthcare products. The Companyâs products include cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza and others. The Company operates through two business segments. The Distribution Sales of Pharmaceutical and Healthcare Products segment is engaged in the distribution and sales of branded imported pharmaceutical and healthcare products primarily in Hong Kong and the Peopleâs Republic of China (PRC). The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment is engaged in the manufacture and sales of electrotherapeutic and physiotherapeutic devices, as well as general medical examination devices in the PRC.
Sector
Pharmaceuticals
Calendar
25/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.70% | 40.87M | |
| +15.79% | 70.45B | |
| +2.09% | 25.03B | |
| -2.98% | 8.05B | |
| +7.95% | 8.29B | |
| -20.48% | 7.97B | |
| +15.26% | 4.25B | |
| -1.24% | 4.04B | |
| -3.16% | 3.86B | |
| +21.10% | 3.61B |
- Stock Market
- Equities
- 1110 Stock
